PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New hope for kidney disease: HRS-5965 aims to slow damage in IgA nephropathy
Disease control Not yet recruitingThis study looks at the long-term safety of an experimental drug called HRS-5965 in people with primary IgA nephropathy, a kidney disease. About 380 adults who have already taken the drug in a previous study will take it again for up to a year. Researchers will track side effects…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC